Compare Brookfield Infrastructure Partners LP (BIP) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Bristol-Myers Squibb Co — how do they compare? Brookfield Infrastructure Partners LP trades at $39.66 (market cap $18.10B), while Bristol-Myers Squibb Co trades at $63.72 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.2× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| BIP | BMY | |
|---|---|---|
Market Cap | $18.10B | $129.94B |
Sector | Industrials | Health |
52-Week High | $42.62 | $65.89 |
52-Week Low | $29.81 | $42.60 |
Enterprise Value | $77.05B | $163.92B |
Dividend Yield | 4.62% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.97, up 5.24% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong analyst support with 13 buy ratings and a consensus price target of $44.67. Recent financials indicate revenue growth to $25.1 billion in 2026, though net income declined to $652 million. The company maintains a dividend yield with recent payouts of $0.46 per share and is undergoing corporate simplification to enhance shareholder value.
BIP presents a mixed outlook; attractive valuation metrics like EV/EBITDA of 6.97 and P/S of 0.72 suggest upside, but consecutive earnings misses and declining profitability margins pose risks. Investors may benefit from infrastructure demand and high dividend yields, yet should monitor execution on earnings targets and debt levels, with institutional sentiment leaning bullish amid macroeconomic uncertainties.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
